Evidence map›Paper›PMID 42457322›Full record

ArticleZhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics2026

[How I treat anaphylaxis in children].

Min Xie, Xia Wang

Abstract readEnglish Abstract
In one paragraph

Article in Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Min XieDepartment of Pediatric Critical Care Medicine, Children's Medical Center, Xiangya Hospital, Central South University, Changsha 410008, China.
Xia WangDepartment of Pediatric Critical Care Medicine, Children's Medical Center, Xiangya Hospital, Central South University, Changsha 410008, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anaphylaxis is a rapid-onset, life-threatening systemic hypersensitivity reaction. Insufficient awareness of this condition in China and delayed or inappropriate use of epinephrine-the core treatment-are major causes of severe outcomes. Based on two clinical cases and the latest domestic and international guidelines, this article systematically describes early recognition and diagnosis of anaphylaxis in children, epinephrine-centered emergency management strategies, and the treatment protocol for refractory anaphylaxis. For classic anaphylaxis, early intramuscular injection of epinephrine into the anterolateral thigh is lifesaving. For refractory anaphylaxis, intravenous continuous infusion of epinephrine should be initiated promptly after two ineffective intramuscular injections, combined with aggressive fluid resuscitation and, if necessary, second-line vasoactive drugs. Antihistamines and corticosteroids are only adjunctive therapies and cannot replace epinephrine. Standardized post-discharge long-term management and the promotion of novel noninvasive delivery routes will further improve prognosis of pediatric anaphylaxis.

Indexed as

AnaphylaxisChildEpinephrineHumansEpinephrineAnaphylaxisChildEpinephrineRefractory anaphylaxis

Identifiers

PMID42457322
PMCPMC13372560

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.